Kymera Therapeutics (KYMR) Net Equity Issued and Repurchased (2020)

Kymera Therapeutics (KYMR) posted quarterly Net Equity Issued and Repurchased of $83.4 million for Q4 2020, up 200.0% quarter-over-quarter from -$83.4 million in Q3 2020.

Kymera Therapeutics (KYMR) Net Equity Issued and Repurchased (2020) Analysis & Trends

Kymera Therapeutics (KYMR) has reported Net Equity Issued and Repurchased for 1 consecutive years, with $83.4 million the latest figure, recorded in Q4 2020.

  • In Q4 2020, Net Equity Issued and Repurchased changed N/A year-over-year to $83.4 million; the TTM figure through Dec 2020 stood at $88.2 million (changed N/A YoY), while the FY2020 annual figure was $88.2 million, up 528.74% from the prior year.
  • Net Equity Issued and Repurchased advanced to $83.4 million in Q4 2020 per KYMR's latest filing, from -$83.4 million in the prior quarter.
  • Across five years, Net Equity Issued and Repurchased topped out at $88.2 million in Q1 2020 and bottomed at -$83.4 million in Q3 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 49.20 Mn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - 141.90 Mn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn -
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -
10 Kymera Therapeutics 9.72 Bn 9.03 Bn - -

Historic Data

Download Data
DateValue
Dec 31, 2020 83.38 Mn
Dec 31, 2020 83.38 Mn
Sep 30, 2020 -83.38 Mn
Sep 30, 2020 -83.38 Mn
Jun 30, 2020 -19,000.00
Jun 30, 2020 -19,000.00
Mar 31, 2020 88.20 Mn
Mar 31, 2020 88.20 Mn